Citation and evidence

Exscientia

18 min full readUpdated 18 references

This article's verification

Report a problem with this article

Edit article
More

Use this article

Raw MarkdownExplore connections

Improve this page

Revision historyDiscuss this article

Topics

AI CompaniesDrug DiscoveryHealthcare AI

Cite this article

Exscientia was a British drug design company that used artificial intelligence and laboratory automation to design small-molecule drug candidates. Andrew Hopkins, then a professor at the University of Dundee, founded it in Scotland in 2012 as Exscientia Limited, and it later made its headquarters at the Oxford Science Park in Oxford, England.[1][2] Exscientia was among the first companies to put AI-designed molecules into human trials: DSP-1181, a candidate for obsessive-compulsive disorder designed with Sumitomo Dainippon Pharma, entered a Phase 1 study in Japan in January 2020.[6][8] The company listed its American depositary shares on the Nasdaq under the ticker EXAI in October 2021.[1] On November 20, 2024, it became a wholly owned subsidiary of Recursion Pharmaceuticals through an all-stock combination, and its shares were delisted.[3][14]

None of Exscientia's molecules reached the market while it was independent. Sumitomo disclosed in January 2022 that it had abandoned DSP-1181, and Exscientia stopped its own lead candidate, the A2A receptor antagonist EXS21546, in October 2023.[4][9] Its wholly owned oncology programs targeting CDK7, MALT1 and LSD1 passed to Recursion.[12] As of November 2026, Recursion was continuing development of the LSD1 inhibitor and seeking partners for the CDK7 and MALT1 inhibitors.[15][16]

History

Founding and early years (2012 to 2019)

Hopkins spent about ten years at Pfizer, from 1998 to 2007, before moving to the University of Dundee, where he held the Chair of Medicinal Informatics from 2007 to 2020.[2] In December 2012 he and colleagues at Dundee and other institutions published a method in Nature for the automated design of ligands against profiles of several drug targets at once. They tested 800 ligand-target predictions for prospectively designed compounds and reported that 75% were confirmed.[5] Exscientia was founded the same year, and Hopkins served as its chief executive from its inception.[2] The University of Dundee later assigned the company patents that Exscientia described as a core part of its intellectual property, in return for a payment of £150,000.[2]

According to its 2021 prospectus, Exscientia was funded only through business performance and collaboration partners from its founding until 2020.[2] Its early work was done under partnerships. In March 2016 it signed a collaboration with Evotec to generate immuno-oncology molecules, and Evotec also invested in several of Exscientia's preferred financing rounds.[2] In June 2016 it signed a research collaboration with Sanofi on target combinations in metabolic disease; under that deal it delivered a bispecific lead molecule in 2019, and Sanofi exercised an option on one of the targets in August 2019.[2] In March 2019 it began a collaboration with Celgene, which Bristol Myers Squibb (BMS) acquired later that year and which BMS expanded with a new agreement in 2021.[1][2] The same year it formed a co-owned rare-disease joint venture with Rallybio and signed a cell-cycle inhibitor discovery deal with GT Apeiron Therapeutics, a company launched by its investor GT Healthcare.[1]

First clinical candidates (2020)

On January 30, 2020, Sumitomo Dainippon Pharma and Exscientia announced that a Phase 1 study of DSP-1181 had begun in Japan, with obsessive-compulsive disorder as the first indication. DSP-1181 is a long-acting serotonin 5-HT1A receptor agonist. The partners said the exploratory research phase took less than 12 months, against an average of 4.5 years with conventional techniques, using Exscientia's platform, which it called Centaur Chemist, together with Sumitomo's experience in monoamine GPCR drug discovery.[6] Exscientia said the molecule was found among 350 synthesised compounds, compared with a typical 2,500.[7] Hopkins called the trial a "key milestone in drug discovery."[4]

Exscientia's first internally developed candidate followed. EXS21546, a selective adenosine A2A receptor antagonist intended as an immuno-oncology treatment, came out of the Evotec collaboration; the company said the candidate was found nine months after the project began, with 163 compounds synthesised. Its first Phase 1a trial started on December 16, 2020.[2] Evotec later exercised its right to opt out of the program, and an April 2021 amendment set its share of any future revenue from it.[2] A Phase 1 study in the United States of a second Sumitomo molecule designed by Exscientia, DSP-0038, was announced in May 2021.[8] The 2021 prospectus described these three as "the first three AI-designed precision drug candidates to enter human clinical trials," a claim the company made about its own molecules.[2]

Funding, acquisitions and IPO (2020 to 2021)

Fundraising grew quickly in 2020 and 2021. Exscientia raised $100.6 million in gross proceeds from its Series C, Junior C and Series C1 shares in 2020 and the first half of 2021, and $225.0 million from its Series D1 shares in April 2021; by June 30, 2021 it had raised £273.9 million ($378.6 million) in total through private placements. In April 2021 it also signed an equity facility with SVF II Excel (DE) LLC, an affiliate of SoftBank Group, giving it access to up to $300 million more.[2] The Bill & Melinda Gates Foundation awarded it a $4.2 million grant in December 2020 for work on malaria, tuberculosis and non-hormonal contraception, and a further $1.5 million in June 2021 for COVID-19 therapeutics.[1]

In August 2021 Exscientia bought Allcyte, an Austrian precision medicine company, for €50.0 million paid roughly half in cash and half in shares. It said the deal would let it evaluate individual patients' biology in primary tumour tissue rather than in cell lines or animal models.[2] Allcyte was merged into an Austrian subsidiary that was renamed Exscientia GmbH.[1]

Exscientia completed its initial public offering on the Nasdaq Global Select Market in October 2021.[1] Its prospectus offered 13,850,000 American depositary shares at $22.00 each. SoftBank's affiliate and the Gates Foundation agreed to buy $125.0 million and $35.0 million of ADSs respectively in concurrent private placements at the same price.[2] The Gates Foundation purchase was tied to a four-year agreement, signed on September 1, 2021, to develop small-molecule treatments for coronaviruses and future pandemic threats, under which Exscientia committed $35.0 million in matching contributions.[2][1]

Partnerships and pipeline changes (2022 to 2023)

In January 2022 Exscientia signed a second collaboration with Sanofi to discover and validate up to 15 targets in oncology and immunology. It received $100 million upfront and could earn up to $5.2 billion in milestones plus royalties.[1] In September 2023 it added a collaboration with Merck KGaA, Darmstadt, Germany, covering three initial targets, with $20 million upfront and up to $674 million in milestones.[1]

The clinical record was harder. In January 2022 Sumitomo disclosed that it had abandoned DSP-1181 after the drug failed to meet the study's criteria; Hopkins told Endpoints News that Exscientia's role had been to design the molecule while Sumitomo made the clinical decisions.[4] In October 2023 Exscientia discontinued internal development of EXS21546 and began winding down its Phase 1/2 trial in relapsed or refractory renal cell carcinoma and non-small cell lung cancer, saying modelling of clinical and preclinical data suggested "it will be challenging for '546 to reach a suitable therapeutic index."[9][4] Hopkins said the trial had not failed and called the move "a strategic decision" to concentrate on two other cancer programs.[4] At the same time the company ended its collaboration with EQRx after EQRx agreed to be acquired by Revolution Medicines, and dropped some projects within the BMS collaboration.[9]

The company opened an automated laboratory at Milton Park in Oxfordshire in June 2023, intended to link AI design with automated chemical synthesis and biological screening.[1] By the end of 2023 it had 483 staff and sites in Oxford, Milton Park, Miami, Boston, Vienna and Dundee.[1]

Leadership change (2024)

On February 13, 2024, the board terminated Hopkins's employment as chief executive for cause, with immediate effect, after an investigation found he had engaged in relationships with two employees that the board judged inappropriate and inconsistent with the company's standards. The company said his conduct did not affect its financial statements or controls.[10] Chairman David Nicholson resigned after the investigation found he had known of the earlier relationship and handled it without consulting the board. Chief scientific officer David Hallett, a former Evotec executive, became interim chief executive, and director Elizabeth Crain became interim chair.[10] In June 2024 the company announced that John Overington, its chief data officer, had become chief technology officer with effect from May 1, 2024.[18]

In July 2024 Exscientia took full ownership of the CDK7 inhibitor GTAEXS617, which it had been developing jointly with GT Apeiron since 2021. It paid $10 million in cash and issued $10 million of its own equity to Apeiron, forgave Apeiron's outstanding debt and surrendered its Apeiron shares, and agreed to pay single-digit royalties.[11]

Combination with Recursion (2024)

On August 8, 2024, Exscientia and Recursion Pharmaceuticals announced a definitive agreement under which Recursion would acquire Exscientia through a scheme of arrangement under English law. Each Exscientia share was to be exchanged for 0.7729 shares of Recursion Class A common stock.[13] The companies said Recursion shareholders would own about 74% and Exscientia shareholders about 26% of the combined company, that the two held about $850 million in cash and cash equivalents at the end of the second quarter of 2024, and that they expected annual synergies of about $100 million.[12] They presented the deal as combining Recursion's biology-focused platform with Exscientia's "precision chemistry design and small molecule automated synthesis capabilities."[12]

The High Court of Justice of England and Wales sanctioned the scheme on November 19, 2024, and it took effect on November 20, 2024, when Exscientia became a wholly owned subsidiary of Recursion. The day before completion, Exscientia's collaboration with BMS ended after the remaining project under it closed.[3] The combined company kept the Recursion name and its Salt Lake City headquarters. Hallett became Recursion's chief scientific officer, Exscientia's finance chief Ben Taylor became chief financial officer and President of Recursion UK, and former Exscientia director Franziska Michor joined Recursion's board.[14]

"Inside the Recursion-Exscientia definitive agreement", official video from Recursion, published August 12, 2024. Watch on YouTube.

Technology

Exscientia described itself as a drug design company that aimed to raise the chance of a drug succeeding by finding and fixing likely points of failure during design.[1] Its stated philosophy was that "every molecule should be designed by an algorithm," using reinforcement learning, deep learning and evolutionary algorithms to generate and select compounds against a target product profile of dozens of parameters at once, rather than optimising potency, selectivity and other properties one after another.[1] The company treated drug design as a learning problem and used active learning to choose which compounds to make and test next.[1] It said its average time from starting new designs to first synthesis of the eventual drug candidate was about one year and that it typically synthesised fewer than a tenth as many compounds as conventional approaches.[1] These figures are the company's own.

Other parts of the platform reported in its filings and updates included:

  • Automated laboratory. The Milton Park facility handled compound management, automated chemical synthesis and automated biological screening, connected to modules for generative design, active learning and AI retrosynthesis planning.[1]
  • Precision medicine. Exscientia imaged primary patient cells exposed to drugs ex vivo and analysed the images with custom deep learning algorithms, alongside single-cell transcriptomics, genomics, epigenetics and proteomics data.[1] The EXCYTE-1 (ovarian cancer, July 2023) and EXCYTE-2 (acute myeloid leukaemia, February 2024) observational studies tested whether ex vivo responses matched patients' clinical responses.[1]
  • Target discovery. In the fourth quarter of 2023 the company began using large language models internally to generate target hypotheses, and it said more than 40% of the targets it was investigating came from its own data, including phenotypic screens, patient samples, knowledge graphs and language model outputs.[1]
  • Structure-based design. In September 2023 it presented an automated kinase design method that it said could produce potent kinase hits on certain targets starting from AlphaFold structures.[9]

The precision medicine work rested on EXALT-1, a prospective study published online in Cancer Discovery in October 2021 by researchers at the Medical University of Vienna and other centres, including Exscientia GmbH. Of 143 patients with advanced aggressive blood cancers, 56 were treated according to an image-based single-cell functional assay of their own cancer cells. At a median follow-up of 23.9 months, 30 of them (54%) had progression-free survival more than 1.3 times longer than on their previous therapy.[17][1]

Drug candidates

The table lists the clinical and late preclinical candidates that Exscientia designed, with their status in the most recent source available.

CandidateMechanismIndicationPartner or ownerStatus
DSP-11815-HT1A receptor agonistObsessive-compulsive disorderSumitomo Dainippon PharmaPhase 1 began 2020-01; abandoned, disclosed 2022-01[6][4]
EXS21546Adenosine A2A receptor antagonistRenal cell carcinoma, NSCLCExscientia (Evotec revenue share)Phase 1 began 2020-12; discontinued 2023-10[2][9]
DSP-00385-HT1A agonist and 5-HT2A antagonistAlzheimer's disease psychosisSumitomo PharmaPhase 1 (US) from 2021-05; ongoing as of 2023-11[8][9]
DSP-23425-HT2A and 5-HT7 antagonistNot disclosedSumitomo PharmaPhase 1 as of 2023-11[9]
EXS4318PKC-theta inhibitorImmunologyBristol Myers SquibbPhase 1 began 2023-02[1]
GTAEXS617 (REC-617)CDK7 inhibitorAdvanced solid tumoursGT Apeiron, then wholly ownedPhase 1/2 ELUCIDATE from mid-2023; Recursion seeking partner as of 2026-10[1][16]
EXS74539 (REC-4539)Reversible, brain-penetrant LSD1 inhibitorSmall-cell lung cancer; other solid tumours and blood cancersWholly ownedIND cleared 2025-01; development continuing as of 2026-10[15][16]
EXS73565 (REC-3565)MALT1 inhibitorB-cell malignanciesWholly ownedUK CTA cleared 2024-12; Recursion seeking partner as of 2026-10[15][16]

Expanded article table

Exscientia had no economic interest in the Sumitomo molecules, which it designed in a pilot "design as a service" program using the first generation of its platform.[1] For the CDK7 program, the company said it identified a molecule meeting all of its profile criteria after testing 136 compounds.[1] For EXS4318, it said the candidate was designed within 11 months and was the 150th molecule synthesised; BMS licensed it in August 2021, triggering a $20 million milestone payment.[1]

At Recursion, the CDK7 inhibitor was renamed REC-617. In December 2024 Recursion presented early data from 19 patients in the ELUCIDATE trial: one heavily pretreated ovarian cancer patient had a confirmed partial response and four had durable stable disease, the maximum tolerated dose had not been reached, and there were no treatment-related discontinuations.[15] In October 2026 Recursion said it would focus its own resources on other programs, including REC-4539, and pursue partnerships to advance REC-617 and REC-3565.[16]

Partnerships

PartnerStartedReported terms
Evotec2016-03Immuno-oncology collaboration, narrowed to A2A antagonists in 2020; Evotec opted out and kept a revenue share[2]
Celgene, then Bristol Myers Squibb2019-03Expanded with BMS in 2021; $75 million in upfront payments across the two deals; ended November 2024[1][3]
Sanofi2016-06Bispecific lead molecule for inflammation and fibrosis delivered in 2019, up to $250 million in milestones[2]
Rallybio2019Co-owned rare-disease joint venture; first candidates against ENPP1; Recursion bought Rallybio's stake in 2025[1][16]
GT Apeiron Therapeutics2019Cell-cycle inhibitors including the CDK7 candidate; Exscientia acquired full rights in 2024[1][11]
Bayer2020Up to three projects, eligible for up to €240 million[2]
Bill & Melinda Gates Foundation2020-12Grants of $4.2 million and $1.5 million; 2021 pandemic agreement with a $35 million share purchase[1][2]
Sanofi2022-01Up to 15 targets; $100 million upfront, up to $5.2 billion in milestones[1]
Merck KGaA, Darmstadt, Germany2023-09Three initial targets; $20 million upfront, up to $674 million in milestones[1]
Open Philanthropy2023-12$2.3 million grant for research on the host interferon response to pandemic influenza[1]

Expanded article table

The Sanofi and Merck KGaA collaborations continued under Recursion. In September 2026 Sanofi took an option on the first development candidate from the 2022 collaboration, an oral small molecule against a dual target in inflammatory disease, which triggered a $10 million milestone payment. Recursion said this brought the upfront and milestone payments achieved from Sanofi under that collaboration to $144 million, and that the candidate was expected to enter Phase 1 trials in 2027.[16]

Finances

Exscientia earned revenue from upfront payments, milestones and service fees under its collaborations and never sold a drug.[2][1] It reported the following results in pounds sterling.

YearRevenueLoss for the year
2021£27.4 million£49.2 million
2022£27.2 million£118.7 million
2023£20.1 million£146.0 million

Expanded article table

At the end of 2023 it held £363.0 million in cash, cash equivalents and short-term bank deposits and had accumulated losses of £349.5 million since its founding.[1]

Reception

Exscientia's 2020 trial start drew wide attention as an early test of AI-designed medicines; Endpoints News noted that the Financial Times called it a "critical milestone for the role of machine learning in medicine."[4] Its later record featured in more skeptical coverage. In October 2023, after EXS21546 was dropped, Endpoints News reported that the first handful of AI-created molecules, Exscientia's two among them, had failed trials or been deprioritised, and grouped the company with BenevolentAI and Recursion as AI's early generation of drug developers. It quoted Patrick Malone of KdT Ventures: "If you take the hype and PR at face value over the last 10 years, you would think it goes from 5% to 90%. But if you know how these models work, it goes from 5% to maybe 6% or 7%."[4]

After the merger

Recursion integrated Exscientia's Centaur Chemist design platform and automated synthesis capabilities into its own operating system and began running legacy Recursion programs through them.[15] Recursion also carved out Exscientia's Austrian operations: in March 2025 it sold Exscientia GmbH to Alpha Biotechnology GmbH, an Austrian start-up building a patient-tissue platform for precision cancer therapeutics, and obtained a 49% equity interest in Alpha as part of the sale.[15][16] In July 2025 Recursion bought Rallybio's interest in RE Ventures I, the rare-disease joint venture Exscientia had formed with Rallybio, for $20.2 million. Its lead asset, the ENPP1 inhibitor REC-102 for hypophosphatasia, was among the internal programs Recursion said in October 2026 it would keep funding.[16]

Continue reading

More to read

Topics:AI CompaniesDrug DiscoveryHealthcare AI

References

  1. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9 ^10 ^11 ^12 ^13 ^14 ^15 ^16 ^17 ^18 ^19 ^20 ^21 ^22 ^23 ^24 ^25 ^26 ^27 ^28 ^29 ^30 ^31 ^32 ^33 ^34 ^35Exscientia plc. "Annual Report on Form 20-F for the fiscal year ended December 31, 2023". U.S. Securities and Exchange Commission, March 21, 2024. sec.gov/...exai-20231231
  2. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9 ^10 ^11 ^12 ^13 ^14 ^15 ^16 ^17 ^18 ^19 ^20 ^21Exscientia plc. "Prospectus: 13,850,000 American Depositary Shares" (Form 424B4). U.S. Securities and Exchange Commission, October 4, 2021. sec.gov/...tm2119783-17_424b4
  3. ^1 ^2 ^3Exscientia plc. "Report of Foreign Private Issuer on Form 6-K" (completion of the transaction with Recursion). U.S. Securities and Exchange Commission, November 20, 2024. sec.gov/...ss4137056_6k
  4. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8Dunn, Andrew. "First AI-designed drugs fall short in the clinic, following years of hype". Endpoints News, October 19, 2023. endpoints.news/...e-clinic-following-years-of-hype
  5. ^Besnard, Jérémy; Ruda, Gian Filippo; Setola, Vincent; et al.; Hopkins, Andrew L. "Automated design of ligands to polypharmacological profiles". Nature 492: 215-220, December 2012. doi.org/...nature11691
  6. ^1 ^2 ^3University of Dundee. "Sumitomo Dainippon Pharma and Exscientia Joint Development New Drug Candidate Begins Clinical Study". University of Dundee News, January 30, 2020. dundee.ac.uk/...new-drug-candidate-begins-clinical
  7. ^Staines, Richard. "Exscientia claims world first as AI-created drug enters clinic". pharmaphorum, January 30, 2020. pharmaphorum.com/...-ai-created-drug-enters-clinic
  8. ^1 ^2 ^3Wills, Todd. "AI drug discovery: assessing the first AI-designed drug candidates to go into human clinical trials". CAS Insights, September 23, 2022. cas.org/...idates-to-go-into-human-clinical-trials
  9. ^1 ^2 ^3 ^4 ^5 ^6 ^7Exscientia plc. "Exscientia Business Update for Third Quarter 2023" (Exhibit 99.3 to Form 6-K). U.S. Securities and Exchange Commission, November 9, 2023. sec.gov/...exai3q23earningspressrelea
  10. ^1 ^2Exscientia plc. "Report of Foreign Private Issuer on Form 6-K" (termination of the chief executive and board changes). U.S. Securities and Exchange Commission, February 13, 2024. sec.gov/...exai-form6xkevenloadfinal1
  11. ^1 ^2Exscientia plc. "Report of Foreign Private Issuer on Form 6-K" (asset purchase of CDK7 from Apeiron). U.S. Securities and Exchange Commission, July 18, 2024. sec.gov/...exai-form6xkgtapeironasset
  12. ^1 ^2 ^3Recursion Pharmaceuticals and Exscientia plc. "Recursion and Exscientia Enter Definitive Agreement to Create A Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities" (Exhibit 99.1 to Recursion Form 8-K). U.S. Securities and Exchange Commission, August 8, 2024. sec.gov/...d856792dex991
  13. ^Exscientia plc. "Report of Foreign Private Issuer on Form 6-K" (entry into transaction agreement). U.S. Securities and Exchange Commission, August 8, 2024. sec.gov/...ss3728016_6k
  14. ^1 ^2Recursion Pharmaceuticals. "Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery" (Exhibit 99.3 to Form 8-K). U.S. Securities and Exchange Commission, November 20, 2024. sec.gov/...exhibit993-closingprexai_r
  15. ^1 ^2 ^3 ^4 ^5 ^6Recursion Pharmaceuticals. "Annual Report on Form 10-K for the fiscal year ended December 31, 2024". U.S. Securities and Exchange Commission, February 28, 2025. sec.gov/...rxrx-20241231
  16. ^1 ^2 ^3 ^4 ^5 ^6 ^7 ^8 ^9Recursion Pharmaceuticals. "Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026". U.S. Securities and Exchange Commission, November 2, 2026. sec.gov/...rxrx-20260930
  17. ^Kornauth, Christoph; Pemovska, Tea; Vladimer, Gregory I.; et al. "Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders". Cancer Discovery 12(2): 372-387, February 2022. doi.org/...2159-8290.CD-21-0538
  18. ^Exscientia plc. "Report of Foreign Private Issuer on Form 6-K" (promotion of executive officer). U.S. Securities and Exchange Commission, June 6, 2024. sec.gov/...exai-form6xkexectransitions

Improve this article

Add missing citations, update stale details, or write a clearer explanation. Anyone can edit: changes go live when you publish, and every edit is checked by an editor.

2 revisions · v2 · 3,578 words · full history

Fact-checks are independent of edits: a reviewer re-verifies the article against its sources and stamps the date. How we verify

Research and drafting on this wiki are AI-assisted, under named human editorial standards. How AI is used here

Reviewer note: Independent fact-check before publication on November 18, 2026: 112 claims checked against 20 cited and independent sources; 1 material and 3 minor corrections applied before publication.

Cite this page: AI Wiki. "Exscientia." aiwiki.ai, updated 18 Nov 2026, fact-checked 18 Nov 2026. CC BY 4.0. https://aiwiki.ai/wiki/exscientia

Edit article